Objective-The ATP-binding cassette transporter, subfamily A, member 1 (ABCA1) plays a key role in HDL cholesterol metabolism. However, the role of ABCA1 in modulating susceptibility to atherosclerosis is controversial. Methods and Results-We investigated the role of ABCA1 in atherosclerosis using a combination of overexpression and selective deletion models. First, we examined the effect of transgenic overexpression of a full-length human ABCA1containing bacterial artificial chromosome (BAC) in the presence or absence of the endogenous mouse Abca1 gene. ABCA1 overexpression in the atherosclerosis-susceptible Ldlr Ϫ/Ϫ background significantly reduced the development of atherosclerosis in both the presence and absence of mouse Abca1. Next, we used mice with tissue-specific inactivation of Abca1 to dissect the discrete roles of Abca1 in different tissues on susceptibility to atherosclerosis. On the Apoe Ϫ/Ϫ background, mice lacking hepatic Abca1 had significantly reduced HDL cholesterol and accelerated atherosclerosis, indicating that the liver is an important site at which Abca1 plays an antiatherogenic role. In contrast, mice with macrophage-specific inactivation of Abca1 on the Ldlr Ϫ/Ϫ background displayed no change in atherosclerotic lesion area.
T he ATP binding cassette transporter, subfamily A, member 1 (ABCA1) regulates the rate-limiting step in the biogenesis of high-density lipoprotein (HDL) particles by mediating the efflux of cellular cholesterol and phospholipids to apolipoprotein A-I (apoA-I) and therefore plays a critical role in reverse cholesterol transport. 1 Mutations in ABCA1 in humans cause Tangier disease (TD), characterized by nearly absent HDL cholesterol and lipid accumulation in tissue macrophages. Several recent genome-wide association studies have identified common variants in ABCA1 as a significant source of variation in plasma HDL cholesterol levels across multiple ethnic groups, 2-4 establishing ABCA1 as a major gene influencing HDL levels in humans.
Despite the known role of ABCA1 in determining plasma HDL levels, the impact of ABCA1 on atherosclerosis remains controversial and incompletely understood. TD patients have increased risk of coronary artery disease relative to related controls, 5, 6 though perhaps not as great a risk as would be expected based on their extremely low HDL cholesterol levels. In contrast, a recent study suggested that low HDL caused by loss-of-function mutations in ABCA1 does not contribute to risk of cardiovascular disease in the general population. 7 Studies in mouse models have also yielded conflicting results. Mice lacking Abca1 globally exhibit no change in susceptibility to atherosclerosis. 8 However, deletion of Abca1 in bone marrow-derived hematopoietic cells results in increased atherosclerosis, 8 -10 and overexpression of bone marrow Abca1 reduces atherosclerosis. 11 Conversely, transgenic mice significantly overexpressing Abca1 in liver and macrophages have increased plasma HDL cholesterol and apolipoprotein B (apoB) levels, 12 yet have increased atherosclerosis on genetic backgrounds lacking either apolipoprotein E (Apoe Ϫ/Ϫ ) 13 or the low density lipoprotein receptor (Ldlr Ϫ/Ϫ ). 14 These data led to the hypothesis that hepatic Abca1 may actually play a proatherogenic role in vivo 15, 16 by virtue of its effect on the metabolism of apoBcontaining lipoproteins.
Here we addressed the role of ABCA1 in atherosclerosis using two complimentary approaches. We first determined the effect of physiological overexpression of a full-length ABCA1-containing bacterial artificial chromosome (BAC) on the Ldlr Ϫ/Ϫ background, in the presence or absence of the endogenous mouse Abca1 gene. We then investigated in which tissues ABCA1 exerts its effect on atherosclerosis using mice with tissue-specific inactivation of Abca1. We hypothesized that ABCA1 in either the liver, by virtue of its key role in HDL biogenesis, 17 or the macrophage, because of its role in removal of vessel wall cholesterol, could impact atherogenesis. We therefore studied mice that specifically lack either hepatic or macrophage Abca1, on the Apoe Ϫ/Ϫ and Ldlr Ϫ/Ϫ backgrounds, respectively. Our results indicate that ABCA1 overexpression protects against atherosclerosis on the Ldlr Ϫ/Ϫ background, and that hepatic Abca1 is an important site of ABCA1-mediated atheroprotection.
Methods and Materials
Detailed descriptions of animals, reagents, and methods are described in the supplemental methods section (available online at http://atvb. ahajournals.org). All studies were approved by institutional review boards. Protein expression lipoprotein analysis and atherosclerosis measurements were performed as previously described. 18 -20 
Results
Previous studies have examined atherosclerosis in ABCA1 BAC transgenic mice on the Apoe Ϫ/Ϫ background. 20 However, subsequent to this study, it was found that the BAC studied lacked exon 1 of the ABCA1 gene. 21 We therefore used recently described transgenic mice containing a full-length human ABCA1 BAC including 25 kilobases of upstream promoter sequence. 18 Use of the full-length BAC most faithfully models the endogenous gene and allows more accurate study of increasing ABCA1 with its appropriate regulatory elements results on susceptibility to atherosclerosis. ABCA1 BAC mice were crossed to Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ mice fed a chow or Westerntype diet (WTD). Expression of ABCA1 protein in the livers and macrophages of these mice was determined by Western immunoblotting and indicated that ABCA1 was significantly increased in both the livers ( Figure 1A ) and macrophages ( Figure  1B ) of BACϩ; Ldlr Ϫ/Ϫ and BACϩ; Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ mice. The levels of ABCA1 protein were further increased when the BACϩ; Ldlr Ϫ/Ϫ and BACϩ; Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ mice were fed a Western-type diet (WTD) containing 0.25% cholesterol and 15% cocoa butter ( Figure 1A and 1B), indicating that the BAC contains regulatory elements that respond physiologically to dietary signals. 20 Plasma lipid and lipoprotein levels in BACϩ; Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice are shown in supplemental Figure I . Increased expression of ABCA1 resulted in a small increase in total cholesterol, very-low-density lipoprotein (VLDL) cholesterol, and low-density lipoprotein (LDL) cholesterol on a chow diet. However, these differences were not statistically significant when mice were fed a WTD (supplemental Figure I) . Plasma HDL cholesterol levels were not significantly different between BACϩ; Ldlr Ϫ/Ϫ and Ldlr Ϫ/Ϫ mice on either chow or WTD (supplemental Figure I) . These data indicate that expression of ABCA1 in Ldlr Ϫ/Ϫ mice did not result in substantial changes in plasma HDL cholesterol levels or the overall lipid profile.
Expression of human ABCA1 in Ldlr Ϫ/Ϫ mice did not result in significant differences in atherosclerotic lesion area (Ldlr Ϫ/Ϫ : 25.6Ϯ4.0 mm 2 versus BACϩ; Ldlr Ϫ/Ϫ : 39.8Ϯ12.8 mm 2 , nϭ5, Pϭns; Figure 2 ), likely reflecting the small increase in ABCA1 protein observed in these mice, as well as the relatively small lesion area observed. On a WTD, where ABCA1 protein expression was further increased, a significant 2-fold reduction in lesion area was observed in the Ldlr Ϫ/Ϫ mice expressing the ABCA1 BAC (Ldlr Ϫ/Ϫ : 491.1Ϯ173.30 mm 2 versus BACϩ; Ldlr Ϫ/Ϫ : 211.5Ϯ115.4 mm 2 , nϭ5, Pϭ0.02; Figure 2 ).
Because both human and mouse ABCA1 are present in the Ldlr Ϫ/Ϫ and BACϩ; Ldlr Ϫ/Ϫ mice, and because both genes respond to feeding of WTD (Figure 1 ), the reduced susceptibility to atherosclerosis we observed in these mice could be accounted for by either the human ABCA1 transgene, the endogenous murine Abca1 gene, or a combination of both. To determine the antiatherogenic properties of human ABCA1 without the potential contribution of the endogenous mouse gene, we next assessed atherosclerosis in mice globally deficient for mouse Abca1 with or without the human ABCA1 BAC. Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ double knock-out mice had reduced plasma total cholesterol, HDL cholesterol, and triglyceride levels compared to Ldlr Ϫ/Ϫ mice (supplemental Figures I and II), consistent with previous reports. 8 When the ABCA1 BAC transgene was introduced to the Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ double knock-out mice, plasma HDL cholesterol, apoA-I and apoA-II levels were significantly increased on both the chow and WTD (supplemental Figure II) , indicating that human ABCA1 expression alone was sufficient to raise plasma HDL cholesterol levels in this genetic background. On the WTD, the expression of ABCA1 also resulted in increased triglycerides and LDL cholesterol, with no change in VLDL cholesterol levels (supplemental Figure II) .
Expression of human ABCA1 in the Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ double knock-out chow-fed mice resulted in a significant decrease in atherosclerotic lesions (Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ : 18.2Ϯ6.5 mm 2 versus BACϩ; Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ : 4.0Ϯ1.0 mm 2 , nϭ5, Pϭ0.02). This difference was also evident when the mice were fed the WTD (Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ : 560.2Ϯ143.5 mm 2 versus BACϩ; Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ : 292.9Ϯ31.2 mm 2 , nϭ5, Pϭ0.04; Figure 3 ). These data indicate that full-length human ABCA1 expression significantly reduces susceptibility to atherosclerosis in the absence of mouse Abca1.
We next investigated in which specific tissues ABCA1 exerts its major antiatherosclerotic effect by studying mice with tissue-specific deletion of Abca1. We hypothesized that the liver, which is the major site of HDL biogenesis in mice, 17 would be an important site for ABCA1-mediated atheroprotection. To test this hypothesis, we generated mice that specifically lack hepatic Abca1 on the Apoe Ϫ/Ϫ background. Mice deficient for hepatic Abca1 (Abca1 ϪL/ϪL ) 17 on a mixed 129SvEv/C57BL6 genetic background were bred to congenicity on the C57BL6 background by crossing them to wild-type C57BL6 mice through the use of a speed congenic approach.
Hepatic Abca1 protein expression was markedly reduced in Apoe Ϫ/Ϫ :Abca1 ϪL/ϪL mice ( Figure 4A ). The expression of the scavenger receptor class B, 1 (Srb1) in liver was equivalent between genotypes ( Figure 4A ). Thioglycollate-elicted perito-neal macrophages from Apoe Ϫ/Ϫ and Apoe Ϫ/Ϫ :Abca1 ϪL/ϪL mice continued to express Abca1, indicating that the deletion of Abca1 was specific to the liver.
The Table shows plasma lipid and apolipoprotein concentrations in 4-hour fasted 12-week-old Apoe Ϫ/Ϫ and Apoe Ϫ/Ϫ :Abca1 ϪL/ϪL mice. Plasma total cholesterol and phospholipid levels were reduced by 30% and 20%, respectively, in mice lacking hepatic Abca1 (Table) . Plasma HDL cholesterol and apoA-I levels were reduced by Ϸ50% in Apoe Ϫ/Ϫ :Abca1 ϪL/ϪL mice. Plasma LDL and VLDL cholesterol levels were reduced by Ϸ25% and Ϸ35%, respectively (Table) , as has been previously observed in models of selective hepatic Abca1 deficiency. 17, 22 Plasma triglyceride levels were not significantly different between genotypes.
Mice lacking hepatic Abca1 displayed a significant Ϸ75% increase in aortic atherosclerotic lesion area compared to Apoe Ϫ/Ϫ mice (44.4Ϯ30 mm 2 versus 73.3Ϯ34 mm 2 , nϭ4 to 5, PϽ0.01; Figure 4C ). The increase in atherosclerotic lesion area was observed in both male and female mice. Apoe Ϫ/Ϫ ; Abca1 ϪL/ϪL mice also displayed a significant increase in both aortic total cholesterol (PϽ0.05) and free cholesterol (PϽ0.001) levels ( Figure 4D ). These data indicate that hepatic Abca1 plays a key role in protection against atherosclerosis.
To determine whether hepatic lipid content is impacted by absence of hepatic Abca1 and subsequent reduction in hepatic HDL biogenesis, we measured the concentration of lipids in livers of these mice. We observed no difference in the concentration of total or free cholesterol between genotypes (supplemental Figure IVA) . Similarly, phospholipids and triglyceride levels were not altered (supplemental Figure IVB) . Notably, hepatic Srb1 expression was not altered ( Figure 4A ) suggesting that Srb1-mediated uptake of HDL was not altered in the absence of hepatic Abca1.
To assess the contribution of macrophage Abca1 to susceptibility to atherosclerosis, we next examined aortic atherosclerotic lesion area in mice lacking Abca1 in macrophages on the Ldlr Ϫ/Ϫ background. Mice lacking macrophage Abca1 have been recently described 23 and have complete loss of macrophage efflux but no significant change in plasma lipid levels. At 16 weeks of high-fat diet feeding, lesion area was not significantly altered in Ldlr Ϫ/Ϫ ; Abca1 ϪM/ϪM compared to Ldlr Ϫ/Ϫ mice ( Figure 5A ; 540.8Ϯ24 mm 2 v. 484.9Ϯ48 mm 2 , nϭ12; Pϭ0.3). Similarly, aortic lesion area was not significantly altered by the absence of macrophage Abca1 at 12 or 20 weeks of age (data not shown), indicating that macrophage Abca1 does not have a major impact on atherosclerosis.
Discussion
Despite universal acceptance of the crucial role of ABCA1 in maintenance of plasma HDL levels, significant controversy still exists as to its role in influencing susceptibility to atherosclerosis. To determine the role of ABCA1 in atherosclerosis we examined the effects of overexpression or deletion of ABCA1 in different animal models. We first crossed mice expressing a full-length human ABCA1 BAC to Ldlr Ϫ/Ϫ mice and found that the expression of ABCA1 in this background did not result in major alterations in plasma lipids, but did result in a significant reduction in atherosclerotic lesion area when fed a WTD. Assessing the effect of human ABCA1 expression in the absence of mouse Abca1 in Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ double knock-out mice again revealed a significant reduction in atherosclerosis in mice expressing ABCA1 accompanied by an increase in plasma HDL cholesterol levels. These data establish that physiological expression of appropriately regulated ABCA1 reduces atherosclerosis in mice, consistent with previous data. 20 We next used mice with tissue-specific inactivation of Abca1 to determine the specific tissue sites at which Abca1 impacts atherogenesis. The two major candidate sites at which Abca1 might modulate susceptibility to atherosclerosis are the liver, because of its major effect on HDL levels, 17 and the macrophage, implicated in previous studies to impact atherogenesis. 8 -10 Apoe Ϫ/Ϫ ; Abca1 ϪL/ϪL mice developed significantly more atherosclerotic burden compared to control Apoe Ϫ/Ϫ mice, establishing the liver as an important site of ABCA1-mediated atheroprotection. In these mice, it seems likely that the significant reduction in HDL is the major mechanism by which Abca1 modulates susceptibility to atherosclerosis. In contrast, Ldlr Ϫ/Ϫ ; Abca1 ϪM/ϪM mice displayed no increased susceptibility to atherosclerosis at any time point studied, indicating that macrophage Abca1 does not exert a major effect on atherosclerosis.
Our data showing no change in atherosclerosis in mice lacking macrophage Abca1 are unexpected based on previous studies using bone marrow transplantation which showed increased atherosclerosis in lethally-irradiated recipients of Abca1-deficient bone marrow, 8, 9 and which thus extrapolated that deficiency of Abca1 in macrophages was responsible for this effect. A number of substantial methodological differences are likely to explain these divergent results. First, bone marrow transplantation studies involve the depletion of Abca1 in all hematopoietic cells. In contrast, the myeloid specific M lysozyme promoter used to drive Cre expression in Ldlr Ϫ/Ϫ ; Abca1 ϪM/ϪM mice is restricted to macrophages and neutrophils 24 and leads to very low levels of target-gene deletion in dendritic cells and virtually none in lymphocytes, where Abca1 is highly expressed. 25 This may suggest that the increased atherosclerosis observed in mice receiving Abca1 null bone marrow is attributable to loss of Abca1 in lymphocytic, rather than myeloid cells. Furthermore, bone marrow transplantation may also lead to repopulation of bone marrow-derived endothelial progenitor cells, thought to be important in restoration of the endothelium after ischemic injury, 26 whereas this cell population would not be impacted in Abca1 ϪM/ϪM mice. It is possible that lethal irradiation, the bone marrow transplantation procedure, or loss of Abca1 in some population of hematopoietic cells may lead to an immunologic response, as indicated by the significant leukocytosis in recipients of Abca1 null bone marrow, 9 suggesting the creation of an inflammatory milieu that may itself lead to accelerated atherosclerosis.
A further difference is that bone marrow transplantation studies transplanted bone marrow from mice wild-type for the LDL receptor into an Ldlr Ϫ/Ϫ recipient. 9, 10 In contrast, macrophages from Ldlr Ϫ/Ϫ ; Abca1 ϪM/ϪM mice lack both the LDL receptor and Abca1. LDL receptor-deficient macrophages are reported to have significantly reduced Abca1 levels compared to wild-type, 27 implying that Abca1 may already be partially inactivated in macrophages from Ldlr Ϫ/Ϫ mice, and thus limiting the difference that could be expected to be observed between Ldlr Ϫ/Ϫ ; Abca1 ϪM/ϪM and Ldlr Ϫ/Ϫ mice in terms of macrophage Abca1. Further studies on different athero-susceptible genetic backgrounds may help resolve these issues.
Our data agree with a previous study showing no differences in atherosclerotic lesions in Ldlr Ϫ/Ϫ ; Abca1 Ϫ/Ϫ mice when compared to Ldlr Ϫ/Ϫ mice on a high-fat diet. 8 The decrease in endogenous Abca1 in these mice might be expected to increase atherogenesis because of the loss of Abca1 in hepatocytes and the resultant decrease in HDL levels. However, these mice also show a significant decrease in plasma total and non-HDL cholesterol and triglycerides, thereby providing an antiatherogenic lipid profile which may compensate for the reduction in HDL.
Our data are in contrast to a study by Joyce et al, 14 who found significant increases in both a proatherogenic lipid profile and in atherosclerosis when mice overexpressing Abca1 were crossed to Ldlr Ϫ/Ϫ mice. These authors also found significant increases in atherosclerotic lesions in Apoe Ϫ/Ϫ mice expressing Abca1. 13 The reasons for these differences likely reflect the different levels of expression and regulation of ABCA1 in these different animal models. Joyce et al used Abca1 cDNA mice which were driven by the Apoe promoter with its hepatic and macrophage elements, whereas in our mice ABCA1 was driven by the endogenous promoter, which may be necessary to respond to physiological stimuli and for proper expression, subcellular localization and function of ABCA1. The ABCA1 BAC mice in this study had a transgene copy number of two, 18 resulting in a small but significant increase in ABCA1 protein (Figure 1) . In contrast, mice transgenic for the Abca1 cDNA driven by the Apoe promoter had a copy number of 30. 12 High levels of expression of an Abca1 cDNA driven by the CMV promoter may result in nonphysiological subcellular localization of Abca1 and has previously been shown to result in a significant increase in not only HDL cholesterol but in proatherogenic apoB-containing lipoproteins as well 28, 29 which may explain why atherosclerosis was increased in this model.
The relationship between ABCA1 and the metabolism of apoB-containing lipoproteins is not fully understood. Ldlr Ϫ/Ϫ ; Abca1 ϪL/ϪL mice have reduced levels of LDL and VLDL cholesterol, consistent with previous reports of mice lacking hepatic Abca1. 17, 22 Mice lacking intestinal Abca1 also have reduced levels of LDL cholesterol. 30 The reduction in apoB levels in conditions of Abca1 deficiency is hypothesized to be secondary to the reduction in HDL, resulting in a smaller pool of plasma cholesterol for transfer to apoB-containing lipoproteins and their subsequent hypercatabolism. 30 Whether ABCA1 also influences apoB-containing particle metabolism more directly is not known.
In summary, we have demonstrated that physiological expression or deletion of ABCA1 modulates susceptibility to atherosclerosis in mice. Our results identify the liver as an important site at which Abca1 inhibits atherogenesis, suggesting that hepatic ABCA1 may be an appropriate therapeutic target for raising HDL levels and reducing atherosclerosis in humans. Our study does not provide support for the previously held view that macrophage Abca1 influences atherogenesis. Whether Abca1 in other tissues, such as the intestine, lymphocytes, endothelium, or adipose tissue, also influences atherosclerosis is not known, but can now be investigated with the use of tissue-specific deletion models of Abca1. 
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